Cipher Pharmaceuticals Inc CPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CPH is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CAD 8.50
- Day Range
- CAD 8.50–8.57
- 52-Week Range
- CAD 3.11–9.98
- Bid/Ask
- CAD 8.45 / CAD 8.68
- Market Cap
- CAD 204.91 Mil
- Volume/Avg
- 3,900 / 46,989
Key Statistics
- Price/Earnings (Normalized)
- 13.18
- Price/Sales
- 7.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.66%
Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6
- Website
- https://www.cipherpharma.com
Comparables
Valuation
|
Metric
|
CPH
|
PROC
|
PGMN3
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.18 | 89.59 | 49.35 |
Price/Book Value | 1.91 | 7.81 | 0.53 |
Price/Sales | 7.56 | 0.67 | 0.11 |
Price/Cash Flow | 8.30 | 6.05 | 4.30 |
Price/Earnings
CPH
PROC
PGMN3
Financial Strength
|
Metric
|
CPH
|
PROC
|
PGMN3
|
|---|---|---|---|
Quick Ratio | 8.55 | 0.97 | 0.37 |
Current Ratio | 9.19 | 1.47 | 1.39 |
Interest Coverage | — | 2.77 | 0.48 |
Quick Ratio
CPH
PROC
PGMN3
Profitability
|
Metric
|
CPH
|
PROC
|
PGMN3
|
|---|---|---|---|
Return on Assets (Normalized) | 25.36% | 0.21% | −0.16% |
Return on Equity (Normalized) | 28.77% | 7.45% | −0.58% |
Return on Invested Capital (Normalized) | 26.71% | 10.39% | 6.02% |
Return on Assets
CPH
PROC
PGMN3
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Jddfqvkc | Mdzlk | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Drztzlbj | Rbpcyjm | $70.8 Bil | |
HLN
| Haleon PLC ADR | Lqsfkmglx | Dshc | $38.2 Bil | |
VTRS
| Viatris Inc | Snhzfmpjl | Jkrs | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fcjwjpv | Rgtd | $12.5 Bil | |
CTLT
| Catalent Inc | Wknzypt | Ycsyg | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Ckyhxfh | Twkz | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Wtndpcgp | Qrn | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jmkkwhxn | Khwwgh | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Tznbvlkqb | Fmhw | $2.9 Bil |